Global Radioimmunotherapy Market, Dosage, Price and Clinical Pipeline Outlook 2022

Download Sample

For Report Sample Contact: neeraj@kuickresearch.com

Report Weblink: https://www.kuickresearch.com/report-global-radioimmunotherapy-market,-dosage,-price-and-clinical-pipeline-outlook-2022.php

Table of Contents

1. Cancer Radioimmunotherapy - Amalgamation Therapy for Elevated Efficacy
1.1 Prologue to Cancer Radioimmunotherapy
1.2 History and Evolution of Cancer Radioimmunotherapy

2. Radioimmunotherapy - An insight into its Need and Efficacy
2.1 High Unmet Medical Needs and Failure of Conventional Cancer Therapeutics
2.2 Targeted Therapy for Higher Efficacy
2.3 Superiority of Radioimmunotherapy over Other Cancer Therapeutics

3. Features of Radioimmunotherapy
3.1 Approved Benefits Associated with Radioimmunotherapy
3.2 Radioimmunotherapy using Monoclonal Antibodies

4. Components of Radioimmunotherapy
4.1 Tumor Antigens - Potential Targets for Monoclonal Antibodies
4.2 Radionuclides
4.3 Antibodies - Key Components in Radioimmunotherapy

5. Radioimmunotherapy - Principle and Action

6. Clinical Status of Radioimmunotherapy in Various Cancer Therapy
6.1 Non Hodgkin Lymphoma (NHL)
6.2 Follicular Lymphoma
6.3 Solid Tumors
6.4 Breast Cancer
6.5 Ovarian Cancer
6.6 Osteosarcoma
6.7 Neuroblastoma
6.8 Prostate Cancer

7. Emerging Opportunities and Avenues in the Radioimmunotherapy Segment
7.1 Immune Checkpoint Inhibitors and Radioactive Iodine in Cancer Radioimmunotherapy
7.2 Nanotechnologically Created Radiotracer: For Efficient Delivery of Radioactivity in Tumor Cells

8. Radioimmunotherapy Market - Dosage and Price Analysis of Monoclonal Antibodies involved
8.1 Ibritumomab tiuxetan (Zevalin) and Rituxanandndash; Dosage and Price Analysis in Follicular B-cell Non-Hodgkin Lymphoma
8.2 Zevalin and Rituxan: Therapy Cost Analysis
8.3 Comparative Cost Analysis of Radioimmunotherapy with Traditional Cancer therapy Methods
8.4 Tositumomab and iodine I 131 Tositumomab (Bexxar)

9. Market Performance and Trends in Radioimmunotherapeutics Segment
9.1 Better Safety and Efficacy but Limited Growth Opportunity
9.2 Decreasing Sales of Zevalin Threatening the Radioimmunotherapy Market
9.3 Involvement of Blockbuster Therapeutics in Radioimmunotherapy to Ensure Stability in the Future
9.4 Emerging Pattern of Radioimmunotherapy Drug Referrals

10. Radioimmunotherapy Monoclonal Antibodies Currently Under Development and Their Market Potential
10.1 Epratuzumab
10.2 Lintuzumab
10.3 Labetuzumab
10.4 Trastuzumab (Herceptin)

11. Antibodies in Radioimmunotherapy - Patent Analysis

12. Regional Analysis of the Radioimmunotherapy Market
12.1 North America
12.1.1 United States (US)
12.1.2 Canada
12.2 Europe
12.2.1 Germany
12.2.2 France
12.2.3 United Kingdom (UK)
12.2.4 Rest of Europe
12.3 Asia - Pacific
12.3.1 China and India
12.3.2 Japan
12.3.3 Australia
12.4 Rest of the World

13. Global Radioimmunotherapy Market Driving Parameters

14. Radioimmunotherapy - Overcoming the Challenges and Shortcomings

15. Future Forecast and Perspective Regarding the Immunotherapy Segment
15.1 Global Approval of Radioimmunotherapy to Enhance Market Growth in Future
15.2 Radiopharmaceutical Market and its Impact on the Radioimmunotherapy market growth
15.3 Other Market Propelling Factors

16. Global Radioimmunotherapy Clinical Pipeline by Company, Indication and Phase
16.1 Global Radiopharmaceuticals Pipeline Overview
16.2 Unknown
16.3 Research
16.4 Preclinical
16.5 Clinical
16.6 Phase-0
16.7 Phase-I
16.8 Phase-I/II
16.9 Phase-II
16.10 Phase-III
16.11 Preregistration
16.12 Registered

17. Competitive Landscape
17.1 Bayer Healthcare Pharmaceuticals
17.2 BioSynthema
17.3 Clarity Pharmaceuticals
17.4 Curasight
17.5 Endocyte
17.6 Immunomedics
17.7 Molecular Insight Pharmaceuticals
17.8 Nordic Nanovector
17.9 PDL Biopharma
17.10 Philogen
17.11 RadioMedix
17.12 Stella Pharma
17.13 Telix Pharmaceuticals

Figure 1-1: Evolution of Radiopharmaceuticals and Radioimmunotherapy
Figure 2-1: Need for Radioimmunotherapy
Figure 4-1: Components or Radioimmunotherapy
Figure 4-2: Monoclonal Antibodies - Vital Target Sites in Immunotherapy
Figure 4-3: Antigen Target and Their Therapy Antibodies in Radioimmunotherapy
Figure 4-4: Development of a Radionuclide
Figure 4-5: Half Life of Various Radioimmunotherapy Nuclides
Figure 4-6: Tissue Penetration of Key Radionuclides Used in Immunotherapy (mm)
Figure 4-7: Monoclonal Antibody in Radioimmunotherapy
Figure 5-1: Fundamental Working Mechanism of Radioimmunotherapy
Figure 6-1: Global - Non Hodgkin Lymphoma Incidence and Mortality by Numbers, 2018
Figure 6-2: Clinical Efficacy- Rituximab v/s Zevalin Standalone Therapy (%)
Figure 6-3: Global - Ovarian Cancer Incidence (per 100,000 Females), 2018
Figure 7-1: Humanized Antibodies - High Efficacy due to decreased Immunogenecity
Figure 8-1: Zevalin - Overview of Dosage Schedule
Figure 8-2: Zevalin- Dosage (milliCurie/kg)
Figure 8-3: Zevalin - Cost Analysis (US$/ml), 2018
Figure 8-4: Rituxan - Dosage (mg/m2)
Figure 8-5: Rituxan - Cost Analysis (US$/ml), 2018
Figure 8-6: Dosage - Median Radiation Dosimetry(Y-90 Zevalin cGy /mCi)
Figure 8-7: Zevalin and Rituxan: Average Therapy Cost Analysis (US$), 2018
Figure 8-8: Comparative Cost Analysis: Radioimmunotherapy v/s Traditional Cancer Therapeutics
Figure 8-9: Overview - Ositumab Dosing Schedule in Non-Hodgkin Lymphoma
Figure 8-10: Tositumab and I 131 Tositumab- Dosage (mg/Session)
Figure 8-11: Radiation dosimetry in Bexaar Therapy
Figure 9-1: Global - Zevalin Sales by Year (US$ Million), 2013-2016
Figure 9-2: Global - Rituxan Market Size (%), 2018
Figure 9-3: Global- Rituxan Sales (US$ Billion), 2015 and 2016
Figure 9-4: Global andndash; Tositumomab Referral Trend Analysis by Practice (%), 2018
Figure 11-1: Patent Status - Monoclonal Antibody in Radioimmunotherapy, 2018
Figure 12-1: Canada - Comparative Price Analysis, RIT v/s Non-RIT treatment Modality (US$), 2018
Figure 13-1: Driving Factors of the Radioimmunotherapy Segment
Figure 14-1: Challenging Aspects of the Radioimmunotherapy Market
Figure 15-1: Zevalin - Sales Future Forecast (US$ Million), 2016-2022
Figure 15-2:Rituxan - Future Sales Forecast (US$ Billion), 2016-2022
Figure 15-3: Probability of Radioimmunotherapy Market Growth (%), 2018
Figure 15-4: Global - Radioimmunotherapy Market Size by End User (%), 2018
Figure 16-1: Global - Radiopharmaceuticals Clinical Pipeline by Phase (%), 2018 till 2022
Figure 16-2: Global - Radiopharmaceuticals Clinical Pipeline by Phase (Number), 2018 till 2022

Kuick Research is a market research and analytics company that provides targeted information for critical decisions at business, product and service levels. We are quick, predictive and known by the recommendations we have made in the past. Our result-oriented research methodology offers understanding of multiple issues in a short period of time and gives us the capability to keep you full with loads of practical ideas. By translating research answers into strategic insight and direction, we not only rate the success potential of your products and/or services, but also help you identify the opportunities for growth in new demographies and find ways to beat competition.

Neeraj Chawla
neeraj@kuickresearch.com
KuicK Research
L29 - L34, First Floor
Block L,Connaught Place
New Delhi-110001
+91-11-47067990

This release was published on openPR.